Healthcare provider profile · identity verified

Sarah Flynn

Physician Assistant · AUGUSTA, ME · NPI 1134847916

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	488	183
Lisinopril	Lisinopril	314	106
Levothyroxine Sodium	Levothyroxine Sodium	306	128
Omeprazole	Omeprazole	272	99
Losartan Potassium	Losartan Potassium	236	87
Hydrochlorothiazide	Hydrochlorothiazide	201	79
Amlodipine Besylate	Amlodipine Besylate	179	63
Gabapentin	Gabapentin	156	59
Albuterol Sulfate Hfa	Albuterol Sulfate	154	66
Simvastatin	Simvastatin	140	45
Metoprolol Succinate	Metoprolol Succinate	130	51
Metformin Hcl	Metformin Hcl	123	49
Rosuvastatin Calcium	Rosuvastatin Calcium	103	45
Pantoprazole Sodium	Pantoprazole Sodium	100	43
Sertraline Hcl	Sertraline Hcl	100	45
Oxycodone Hcl	Oxycodone Hcl	92	27
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	87	23
Metoprolol Tartrate	Metoprolol Tartrate	87	34
Famotidine	Famotidine	84	35
Trazodone Hcl	Trazodone Hcl	84	30
Furosemide	Furosemide	82	28
Tamsulosin Hcl	Tamsulosin Hcl	79	38
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	72	27
Meloxicam	Meloxicam	72	37
Duloxetine Hcl	Duloxetine Hcl	69	27
Alendronate Sodium	Alendronate Sodium	64	28
Fluticasone Propionate	Fluticasone Propionate	64	24
Pregabalin	Pregabalin	63	26
Eliquis	Apixaban	62	29
Tramadol Hcl	Tramadol Hcl	62	26
Escitalopram Oxalate	Escitalopram Oxalate	57	21
Lorazepam	Lorazepam	57	23
Potassium Chloride	Potassium Chloride	51	17
Carvedilol	Carvedilol	49	14
Hydroxyzine Hcl	Hydroxyzine Hcl	48	15
Jardiance	Empagliflozin	44	18
Montelukast Sodium	Montelukast Sodium	44	14
Atenolol	Atenolol	43	16
Clopidogrel	Clopidogrel Bisulfate	41	11
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	41	12
Metformin Hcl Er	Metformin Hcl	40	19
Citalopram Hbr	Citalopram Hydrobromide	39	15
Tizanidine Hcl	Tizanidine Hcl	39	suppressed
Lovastatin	Lovastatin	38	12
Allopurinol	Allopurinol	37	15
Buspirone Hcl	Buspirone Hcl	35	11
Bupropion Xl	Bupropion Hcl	33	13
Ozempic	Semaglutide	33	13
Chlorthalidone	Chlorthalidone	30	11
Fluoxetine Hcl	Fluoxetine Hcl	30	13
Enalapril Maleate	Enalapril Maleate	29	suppressed
Jantoven	Warfarin Sodium	29	suppressed
Methocarbamol	Methocarbamol	29	suppressed
Ropinirole Hcl	Ropinirole Hcl	29	suppressed
Myrbetriq	Mirabegron	28	11
Nystatin	Nystatin	27	15
Paroxetine Hcl	Paroxetine Hcl	27	suppressed
Pravastatin Sodium	Pravastatin Sodium	27	suppressed
Ezetimibe	Ezetimibe	25	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	25	suppressed
Valacyclovir	Valacyclovir Hcl	25	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	25	suppressed
Meclizine Hcl	Meclizine Hcl	24	11
Glipizide	Glipizide	22	12
Propranolol Hcl	Propranolol Hcl	22	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	22	suppressed
Topiramate	Topiramate	22	suppressed
Trulicity	Dulaglutide	22	11
Spironolactone	Spironolactone	21	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	20	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	20	12
Warfarin Sodium	Warfarin Sodium	20	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	19	suppressed
Fluconazole	Fluconazole	19	14
Lansoprazole	Lansoprazole	19	suppressed
Morphine Sulfate Er	Morphine Sulfate	19	suppressed
Ventolin Hfa	Albuterol Sulfate	19	suppressed
Clonidine Hcl	Clonidine Hcl	18	suppressed
Xarelto	Rivaroxaban	18	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	18	suppressed
Clonazepam	Clonazepam	17	suppressed
Diazepam	Diazepam	17	suppressed
Ondansetron Odt	Ondansetron	17	13
Oxybutynin Chloride Er	Oxybutynin Chloride	17	suppressed
Prednisone	Prednisone	17	16
Azelastine Hcl	Azelastine Hcl	16	suppressed
Bupropion Hcl Sr	Bupropion Hcl	16	suppressed
Prazosin Hcl	Prazosin Hcl	16	suppressed
Acyclovir	Acyclovir	15	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Estradiol	Estradiol	15	suppressed
Farxiga	Dapagliflozin Propanediol	15	suppressed
Ibuprofen	Ibuprofen	15	suppressed
Nitroglycerin	Nitroglycerin	15	suppressed
Oxycontin	Oxycodone Hcl	15	suppressed
Alprazolam	Alprazolam	14	suppressed
Celecoxib	Celecoxib	14	suppressed
Diclofenac Sodium	Diclofenac Sodium	14	suppressed
Finasteride	Finasteride	14	suppressed
Hydrocortisone	Hydrocortisone	14	suppressed
Januvia	Sitagliptin Phosphate	14	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	14	suppressed
Spiriva Handihaler	Tiotropium Bromide	14	suppressed
Synthroid	Levothyroxine Sodium	14	suppressed
Digoxin	Digoxin	13	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	13	suppressed
Glipizide Er	Glipizide	13	suppressed
Incruse Ellipta	Umeclidinium Bromide	13	suppressed
Mirtazapine	Mirtazapine	13	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	13	suppressed
Restasis	Cyclosporine	13	suppressed
Rybelsus	Semaglutide	13	suppressed
Ramipril	Ramipril	12	suppressed
Valsartan	Valsartan	12	suppressed
Valtrex	Valacyclovir Hcl	12	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	11	11
Breo Ellipta	Fluticasone/Vilanterol	11	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	11	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	11	suppressed
Levetiracetam	Levetiracetam	11	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	11	suppressed
Ondansetron Hcl	Ondansetron Hcl	11	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	11	11
Striverdi Respimat	Olodaterol Hcl	11	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error